The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment

The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with bortezomib (VMP), with thalidomide (MPT), and with lenalidomide with (MPR-R...

Full description

Saved in:
Bibliographic Details
Main Authors: Garrison, Louis P., Wang, Si-Tien, Huang, Hui, Ba-Mancini, Abbie, Shi, Hongliang, Chen, Kristina, Korves, Caroline, Dhawan, Ravinder, Cakana, Andrew, van de Velde, Helgi, Corzo, Deyanira, Duh, Mei Sheng
Format: Artigo
Language:Inglês
Published: AlphaMed Press 2013
Subjects:
Economics of Oncology Practice
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3556252/
https://ncbi.nlm.nih.gov/pubmed/23299777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0380
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items